title: Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia.
abstract: BACKGROUND
  We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles.
  
  
  METHODS
  A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160mg daily for 8 weeks.
  
  
  RESULTS
  When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6±3% (P=0.014) and hsCRP from 1.10 to 0.90mg/l (P=0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17±4% (P=0.001), insulin sensitivity by 4±1% (as assessed by QUICKI, P=0.009), and decreased plasma levels of leptin and resistin by 4±7% (P=0.022) and 10±3% (P=0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels (r=0.279, P=0.043) or leptin (r=-0.280, P=0.042).
  
  
  CONCLUSIONS
  Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.
authors.affiliation: Gachon University, Incheon, Republic of Korea. kwangk@gilhospital.com
authors.forename: Kwang Kon
authors.initials: KK
authors.lastname: Koh
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Quon
authors.forename: Soo
authors.initials: S
authors.lastname: Lim
authors.forename: Yonghee
authors.initials: Y
authors.lastname: Lee
authors.forename: Ichiro
authors.initials: I
authors.lastname: Sakuma
authors.forename: Youn Hee
authors.initials: YH
authors.lastname: Lee
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Han
authors.forename: Eak Kyun
authors.initials: EK
authors.lastname: Shin
mesh_terms: D054392:Adipokines / Q000097:blood* / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D018592:Cross-Over Studies; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007249:Inflammation; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D010919:Placebos; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D054392:Adipokines; D015415:Biomarkers; D006454:Hemoglobins; D000960:Hypolipidemic Agents; D010919:Placebos; D014409:Tumor Necrosis Factor-alpha; D011345:Fenofibrate